The Invisible Graveyard: Quantifying the Mortality Cost of FDA Efficacy Lag

Website: https://manual.warondisease.org/knowledge/appendix/invisible-graveyard.html Abstract: This study quantifies the cumulative mortality and morbidity costs associated with the Unitary Pre-Market Approval (UPMA) model mandated by the 1962 Kefauver-Harris Amendments. By enforcing efficacy testing prior to market entry, the current regulatory framework imposes an average "Efficacy Lag" of 8.2 years (95% CI: 4.85 years-11.5 years) post-safety verification. Using data from the Tufts Center for the Study of Drug Development (CSDD) and the WHO Global Burden of Disease (GBD) database, we estimate two distinct mortality costs: (1) Historical mortality (1962-2024): approximately 102 million deaths (95% CI: 36.9 million deaths-214 million deaths) died waiting for approved drugs during their approval delays, representing a lower bound excluding drugs never developed due to cost barriers; (2) Future timeline shift: an additional 416 million deaths (95% CI: 225 million deaths-630 million deaths) will eventually die because the disease eradication timeline has been pushed back by 8.2 years (95% CI: 4.85 years-11.5 years). Combined, these represent 7.94 billion (95% CI: 4.43 billion-12.1 billion) Disability-Adjusted Life Years when adjusted for morbidity, with a cumulative economic deadweight loss of approximately \$1.19 quadrillion (95% CI: \$443T-\$2.41 quadrillion) (2024 USD), reflecting 7.94 billion (95% CI: 4.43 billion-12.1 billion) DALYs valued at the standard WHO cost-effectiveness threshold of \$150K (95% CI: \$100K-\$199K)/DALY. The societal cost of Type II Regulatory Errors (delayed access to effective therapies) exceeds the averted cost of Type I Regulatory Errors (market access for ineffective therapies) by a factor of 3.07k (95% CI: 2.88k-3.12k). Summary: After proving a drug is safe, the FDA requires 8.2 years to prove it works before patients can access it. We estimate this delay cost 102 million deaths among people waiting for approved drugs (1962-2024). The human cost in death and disability of blocking good drugs is 3.07k higher than the cost of approving bad ones.